- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07582744
CVFs in SIH: EID vs. PCD CTM
CSF-Venous Fistula Detection in Spontaneous Intracranial Hypotension: Comparative Diagnostic Yields of Energy Integrating Detector Versus Photon Counting Detector CT Myelography
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Spontaneous intracranial hypotension (SIH) is a debilitating condition caused by a spinal CSF leak. One subtype of spinal CSF leak, the CSF-venous fistula (CVF), is a pathologic connection between the CSF-containing nerve root sleeve and an adjacent paraspinal vein. Identifying and localizing the CVF that causes SIH is a critical prerequisite to curative treatment. Visualizing CVFs requires high-quality myelography. Despite improvements in myelographic techniques, CVF identification remains challenging because they are diminutive structures and depend on identifying small volumes of contrast in a paraspinal vein, the "hyperdense paraspinal vein sign."
Compared with EID CT myelography (EID-CTM), PCD-CTM enables much higher spatial resolution and a greater contrast-to-noise ratio, carrying with it the promise of improved detection rates for CVF. Previous publications report early encouraging findings on the benefits of PCD-CTM for CVF detection; however, all prior work has been based on retrospective data. Importantly, these retrospective studies have been biased toward reduced PCD-CTM CVF detection, since only the patients with CVFs that are not definitely identified on EID-CTM undergo PCD-CTM (thus, more challenging cases are completed on the PCD CT). No studies have prospectively demonstrated the additional benefit of PCD-CTM over EID-CTM. Furthermore, no studies have prospectively reported the yield of any type of myelography for CVF detection. Based on the study team's knowledge of these imaging modalities and the imaging appearance of CVFs, PCD-CTM may have a benefit in detecting CVFs that can be missed on EID-CTM, which has been suggested in retrospective studies.
This is a prospective randomized clinical trial designed to assess the diagnostic yield of two different CT scanner types for detecting CSF-venous fistulas (CVFs) during CT myelography. The primary study aim is to compare PCD-CTM to traditional EID-CTM, which is currently the most commonly used technique for CVF detection. Patients meeting inclusion/exclusion criteria will be identified at the Duke CSF Leak Clinic. After informed consent, enrolled participants will be randomized (1:1 allocation) to either PCD-CTM or EID-CTM. CTM technique for both arms will be performed in a standardized manner as part of routine standard of care, as previously published. There will be no additional imaging outside of the current standard of care.
The only intervention in this study is randomization into either of the two imaging arms.
CTM images will be reviewed by the radiologist performing the procedure as part of routine standard of care as well as one additional neuroradiologist. The presence or absence of a CVF will be classified according to the Duke CVF Confidence Score (DCCS). Disagreements will be adjudicated by a third neuroradiologist.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Primary Clinical Research Coordinator
- Número de teléfono: 919-684-7810
- Correo electrónico: latonia.strader@duke.edu
Copia de seguridad de contactos de estudio
- Nombre: Clinical Research Specialist
- Número de teléfono: 919-684-3296
- Correo electrónico: amy.cuddington@duke.edu
Ubicaciones de estudio
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Reclutamiento
- Duke University Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Adult patient,
- Confirmed diagnosis of SIH using International Classification of Headache Disorders criteria (third edition), and
- Brain MRI demonstrating at least one positive imaging finding for SIH (e.g., dural enhancement, venous sinus distention, brain sagging, pituitary engorgement, spontaneous subdural fluid collections).
Exclusion Criteria:
- Prior treatment of a CVF,
- Inability to undergo both exams (EID-CTM and PCD-CTM) if needed for diagnosis,
- Spine MRI demonstrating extradural CSF (confirming CSF leak type other than CVF), and
- inability to provide informed consent.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Photon counting detector CT myelography (PCD-CTM)
|
Randomization (1:1) to either photon counting detector CT myelography (PCD- CTM) or energy integrating detector CT myelography (EID-CTM)
|
|
Otro: Energy integrating detector CT myelography (EID-CTM)
|
Randomization (1:1) to either photon counting detector CT myelography (PCD- CTM) or energy integrating detector CT myelography (EID-CTM)
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Diagnostic Yield of CTM for CVF Detection Using DCCS
Periodo de tiempo: Initial interpretation by radiologist performing procedure: within 4 weeks of completion of CTM. Secondary interpretation by additional neuroradiologist and adjudication by third (when needed): completion of study (approximately 3 years)
|
Diagnostic yield will be calculated in both arms as the fraction of patients in whom at least one definite CVF (DCCS 3) is identified.
CTM images from both arms will be reviewed by the radiologist performing the procedure as part of routine standard of care, as well as one additional neuroradiologist.
The presence or absence of a CVF will be classified according to the Duke CVF Confidence Score (DCCS).
Disagreements will be adjudicated by a third neuroradiologist.
|
Initial interpretation by radiologist performing procedure: within 4 weeks of completion of CTM. Secondary interpretation by additional neuroradiologist and adjudication by third (when needed): completion of study (approximately 3 years)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Timothy J Amrhein, MD, Duke University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- Pro00118497
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .